Form 4: Opus Genetics CFO Granted 400,000 Restricted Stock Units

Opus Genetics' Chief Financial Officer, Robert E. Gagnon, was granted 400,000 restricted stock units, vesting quarterly over four years.

Summary

• Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc., acquired 400,000 shares of common stock on January 22, 2026.
• The acquisition was a grant of restricted stock units (RSUs) at a transaction price of $0 per share.
• These RSUs will vest in substantially equal quarterly installments over the next sixteen quarters (four years) from the grant date.
• Vesting is contingent upon Mr. Gagnon's continued service to the company.
• Following this transaction, Mr. Gagnon directly beneficially owns a total of 600,000 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is generally a positive signal, indicating management retention and alignment with long-term company performance. While not a direct cash investment, it ties the CFO's financial interests to the company's success over an extended period.

Positives

• The grant of restricted stock units aligns the Chief Financial Officer's interests with long-term shareholder value.
• The four-year vesting schedule encourages the retention of key management personnel, promoting stability and continuity in leadership.

Future Outlook

The vesting schedule for the restricted stock units extends over the next sixteen quarters, indicating a long-term incentive structure designed to retain the Chief Financial Officer and align their performance with the company's sustained growth.

Industry Context

Equity grants, particularly restricted stock units with multi-year vesting schedules, are a common form of executive compensation in the biotechnology and pharmaceutical industries. This practice is widely adopted to attract and retain top talent, aligning management incentives with long-term company performance and shareholder interests, especially given the extended development timelines inherent in the sector.

Comparison to Industry Standards

• The grant of 400,000 restricted stock units to a Chief Financial Officer is a standard practice for executive compensation, comparable to similar grants observed at early-stage biotech companies like Beam Therapeutics or Editas Medicine, which frequently utilize equity to incentivize leadership given the long development cycles.
• A four-year quarterly vesting schedule is typical for executive equity awards, mirroring industry benchmarks designed to ensure long-term commitment and performance, similar to compensation structures at companies such as Moderna or BioNTech for their senior executives.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's interests with long-term shareholder value, potentially leading to more focused management decisions aimed at increasing stock price. However, it also represents potential future dilution as shares vest.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale and confidence within the company.

Next Steps

• The 400,000 restricted stock units will vest in substantially equal quarterly installments over the next sixteen quarters, commencing from the grant date of January 22, 2026.
• Continued service by the Reporting Person is required for the vesting of the restricted stock units.

Key Dates

Keywords

Opus Genetics, IRD, Robert E. Gagnon, CFO, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Equity Grant, Executive Compensation